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Abstract The identification of prognostic factors in cutaneous
melanoma allows choosing the most effective treatment, espe-
cially in group of patients with locoregional disease. Markers
related to carcinogenesis and angiogenesis in particular have
effect on the course of the disease. The aim of this study was
to evaluate clinical utility of vascular endothelial growth factor
(VEGF), matrix metalloproteinase 2 (MMP-2), MMP-9, tissue
inhibitors of metalloproteinase 1 (TIMP-1), and YKL-40 in
serum of melanoma patients at pathological stages I–III. We
included 148 adult patients with melanoma. The median
follow-up was 40 months. Disease recurrence was observed
in 43 patients; 3-year disease-free survival (DFS) rate was
71.7 %; 35 patients died; and the 3-year overall survival (OS)
rate was 85 %. Concentrations of VEGF, MMP-2, MMP-9,
TIMP-1, and YKL-40 were measured by ELISA kits. VEGF,
MMP-9, TIMP-1, and YKL-40 were significantly higher in
group of patients than in controls. Increased concentrations of
TIMP-1 were related to patient survival, which in the group of
lower and increased TIMP-1, disease-free survival amounted to
81 vs. 61 % (p=0.014) and overall survival −88 vs. 82 % (p=
0.050), respectively. An increased concentration of YKL-40
was observed in 59 % of patients with ulceration and in 26 %
of patients without ulceration (p=0.012). We have found a clin-
ically significant correlation between YKL-40 and MMP-9
(rho=0.363; p=0.004) as well as YKL-40 and VEGF (rho=
0.306; p=0.018). In melanoma patients at stages I–III, the high
concentrations of TIMP-1 in serum predicted adverse progno-
sis. YKL-40 was associated with ulceration of primary tumor,
which is a very important prognostic factor.
Keywords Melanoma . Prognosis . Early stage . Serum
Introduction
Melanoma is amalignant tumor deriving from neuroectodermal
melanocytes, and it is one of the most aggressive cancers in
humans. Depending on the clinical stage determined in accor-
dance with the classification of the American Joint Committee
on Cancer (AJCC), patients are qualified to prognostic groups
and linked to the optimal scheme of treatment. The AJCC clas-
sification is based on the following clinicopathological factors:
depth of invasion (Breslow’s depth), ulceration, mitotic index,
lymph nodes involvement, presence of distant metastases, as
well as concentration of lactate dehydrogenase (LDH) [1]. Al-
though the AJCC classification correctly stratifies patients to
the risk groups, there is still 50 % of patients with locoregional
stage who recur. Therefore, it is worth to consider to add other
prognostic factors which are, e.g., related to tumor biology.
Neoangiogenesis is one of the most important processes of
tumor development, and vascular endothelial growth factor
(VEGF) is a key factor stimulating endothelial cell prolifera-
tion, survival, and migration, as well as leading to the increase
in permeability of blood vessels. The process of neoangiogenesis
is modulated by the activity of matrix metalloproteinases
(MMPs) including MMP-2 and MMP-9, and their tissue
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inhibitor of metalloproteinase 1 (TIMP-1) [2]. The glycoprotein
YKL-40, known as chitinase 3-like 1 (CHI3L1), also increases
the migration of endothelial cells and leads to VEGF over-
expression [3].
The effect of MMP activity is the degradation of extracel-
lular matrix and plasmamembrane of cells which activates the
release of VEGF, bFGF, and other factors related to
neoangiogenesis. MMPs (MMP-2 (gelatinase A) and MMP-
9 (gelatinase B)) degrade type IV collagen—the main compo-
nent of extracellular matrix and the basement membrane of
vessels. This process enables dissemination of tumor cells to
circulation. TIMPs including TIMP-1 also play a significant
role in tumor development through participation in the degra-
dation of extracel lular matrix, in the process of
neoangiogenesis and apoptosis, as well as in proliferation of
normal and tumor cells [4, 5].
In neoangiogenesis, YKL-40—a 38-kDa glycoprotein
binding heparin (gp38k) is released by the number of cells
such as chondrocytes, smoothmuscle cells, active neutrophils,
macrophages, tumor-associated macrophages (TAM), and tu-
mor cells, and is characterized by multidirectional activity
such as involvement in the neoangiogenesis and reconstruc-
tion of extracellular matrix [2].
So far, published data has demonstrated that the tissue
over-expression of VEGF, MMP-2, MMP-9, and TIMP-1
has an adverse effect on the course of the disease and survival
of melanoma patients [6–9]. Only several publications have
concerned the evaluation of the utility of measurements of
VEGF, MMP-2, MMP-9, TIMP-1, and YKL-40 in serum in
melanoma; what is more, the results are controversial [10–17].
The aim of the study was to define clinical utility of serum
biomarkers: VEGF, MMP-2, MMP-9, TIMP-1, and YKL-40
in patients with skin melanoma at locoregional stage.
Patients and methods
Study population
This prospective study included melanoma patients treat-
ed in the Department of Soft Tissue/Bone Sarcoma and
Melanoma in Maria Sklodowska Curie Memorial Cancer
Center and Institute of Oncology (COI), in Warsaw, Po-
land between 2009 and 2010. We included 148 adult
patients (median age 55 years) with pathologically con-
firmed primary melanoma at stages I–III. Patients were
treated according to the national guidelines: sentinel
lymph node biopsy (SLNB) with excision of the primary
tumor (or scar after excisional biopsy) was performed
[18]. Patient characteristics are presented in Table 1. Me-
dian follow-up was 40 months. The study has been ap-
proved by the local bioethics committee.
Healthy controls
The ranges of serum markers were determined in 50 subjects
(median age 42 years, range 19–74 years). They were all
healthy (not taking any medicine, without any clinical signs
or symptoms of cancer, liver, joints, metabolic or hormonal
disease).
Methods
Venous blood was taken from patients before surgical treat-
ment. In order to standardize clotting conditions, all sera were
separated within 1 h after blood collection and stored in
−70 °C until assayed. Concentrations of VEGF, MMP-2,
MMP-9, and TIMP-1 were measured by ELISA kits of
R&D Systems, Minneapolis, USA. YKL-40 was determined
Table 1 Clinical characteristics of the study population





Median (range) 55 (20–76)
Anatomic site of primary tumor
Trunk 61 (41.2)
Lower extremity 51 (34.5)





















Median (range) 40 (2–58)
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by ELISA assays (Quidel, Santa Clara, CA, USA). Normal
levels of serum VEGF, MMP-2, MMP-9, TIMP-1, and YKL-
40 had been previously determined in 50 healthy volunteers.
The number of patients analyzed with each biomarker was
different due to the limited amount of serum stored from each
patient in our tissue bank. The numbers of examined samples
were as follows in patient group: VEGF—148, TIMP-1—
146, MMP-2—113, MMP-9—113, and YKL-40—60, and
in the control group: VEGF—50, TIMP-1—48, MMP-2—
40, MMP-9—38, and YKL-40—18.
Statistical analysis
Patient demographics, tumor characteristics, and treatment de-
tails were analyzed in a descriptive manner. To analyze the
differences of variables between the groups, the chi-square
test for categorical variables, and the Mann-Whitney U test,
the Kruskal-Wallis test, or Dunn post hoc test for continuous
variables were applied. The correlation coefficients between
serum markers were calculated using the Spearman’s rank
correlation, and rho above 0.3 was considered as clinically
significant. In the analyses of prognostic role of serum
markers in survival, the cut-off point for YKL-40 equal
80 ng/ml was based on published data [19], whereas for
VEGF,MMP-9, and TIMP-1, the medians of these parameters
from our melanoma patients were used as cut-off points. The
disease-free survival (DFS) time was calculated from the start
of SLNB/lymphadenectomy to the most recent follow-up or
disease recurrence, while the overall survival (OS) time from
SLNB to the most recent follow-up or death. The impact of
clinicopathological and biochemical factors on DFS and OS
was estimated in the univariate analyses according to Kaplan-
Meier method, and log-rank tests were used for comparisons,
while in the multivariate analyses, Cox proportional hazards
regression model was applied.
Statistical calculations were performed using IBM-SPSS
v.18.0 software. The differences were considered as statisti-
cally significant if p value was <0.05.
Results
The serum biomarkers in melanoma and control group
The patients with melanoma in comparison with the reference
group had significantly higher median concentrations of
VEGF (399 vs. 94 pg/ml; p=000.1), MMP-9 (741 vs.
415 ng/ml; p<0.001), TIMP-1 (161 vs. 116 ng/ml;
p<0.001), and YKL-40 (59 vs. 43 ng/ml; p=0.001). The con-
centrations of MMP-2 were similar in these both groups (in-
creased values only in three patients). Therefore, MMP-2 was
excluded from further statistical analyzes.
In pairwise comparisons of the patients with melanoma at
stages I, II, and III with control group, all differences inVEGF,
MMP-9, TIMP-1, and YKL-40 serum levels between patients
and controls were statistically significant except for the differ-
ence in YKL-40 concentration between melanoma stage I
patients and healthy individuals (Fig. 1). In melanoma pa-
tients, median levels of the studied biomarkers did not differ
between consecutive clinical stages I–III.
The increased value of YKL-40 was observed in 59 % of
patients with ulceration, whereas only in 26 % of patients
without ulceration (p=0.012). No significant correlations ap-
peared between concentrations of TIMP-1, MMP-9, and
VEGF and clinicopathological parameters.
The correlations between serum markers in melanoma
While analyzing the relationship between concentrations of
biomarkers, the most significant values of correlation coeffi-
cient were determined between YKL-40 and MMP-9 (rho=
0.363; p=0.004) as well as YKL-40 and VEGF (rho=0.306;
p=0.018). Remaining correlation coefficients assumed to be
not clinically important ranged from 0.195 to 0.271 (Fig. 2).
Clinical prognostic factors in melanoma
Disease recurrence after primary treatment was diagnosed in
43 patients (29.1 %); 3-year DFS rate was 71.7 % and 5-year
DFS rate was 60 %. Thirty five patients died at the time of
analysis; the 3-year OS rate was 85 %, while 5-year OS rate
was 58.5 %.
In those patients in which recurrence appeared, the concen-
trations of the inhibitor of metalloproteinase TIMP-1 were
significantly higher than in the group without recurrence
(p=0.045); the similar observation was done in patients who
died (p=0.034) in comparison to the patients who survived.
Kaplan-Meier analysis of survival demonstrated that in the
group of patients with increased concentration of TIMP-1 at
the time of diagnosis, the percentage of survivors was signif-
icantly lower than in group where the concentration of TIMP-
1 was below cut-off point. This observation concerned both 3-
year DFS and 3-year OS, which were 61 vs. 81 % (p=0.014)
and 82 vs. 88 % (p=0050), respectively (Table 2, Fig. 3).
A relation between the concentration of YKL-40 and dis-
ease recurrence has also been observed. In the group with
higher YKL-40 level, the recurrence was observed in 53 %
of patients, while in the group with lower YKL-40, the recur-
rence was observed only in 30 % of them, although p value
did not reach statistical significance (p=0.090). In case of
increased concentration of YKL-40, the survival rate was low-
er than in group with YKL-40 below 80 ng/ml. Observed
differences in the 3-year DFS and 3-year OS rates amounted
to 59.4 vs. 77 % and 78.9 vs. 92.5 %, respectively. The
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difference was not statistically significant, probably due to the
small sample size (Table 2, Fig. 4).
A univariate analysis confirmed prognostic role of well-
known clinical factors such as depth of infiltration, nodal in-
volvement, ulceration (parameters included in the AJCC clas-
sification), and TIMP-1 (Table 2). In multivariate Cox regres-
sion model, factors significantly associated with 3-year DFS
remain pN (HR=1.87, p=0.007) and TIMP-1 level
>160 ng/ml (HR=2.03, p=0.041), while factor significantly
associated with 3-year OS was only pN (HR=2.3, p=0.002).
Discussion
The effect of the interaction between cancer cells and tumor
microenvironment very often results in increased concentra-
tions of numerous biomarkers in serum. Biomarkers which
concentration is related to clinicopathological parameters or
survival may act as tumor markers. In the presented study, we
have evaluated a clinical utility of the concentrations of
VEGF, MMP-2, MMP-9, TIMP-1, and YKL-40 in serum of
patients with skin melanoma at locoregional disease. The con-
centrations of VEGF, MMP-9, TIMP-1, and YKL-40 were
significantly higher in patients with melanoma than in control
group. From analyzed biomarkers, increased concentrations
of TIMP-1 appeared to be a negative prognostic factor for
both DFS and OS. It has been also demonstrated that in-
creased concentrations of YKL-40 are caused by the presence
of ulceration.
In melanoma, various studies dedicated to VEGF concen-
tration in serum and its clinical utility were reviewed by
Dewing D et al. [20]. Authors concluded that elevated serum
levels of VEGF strongly correlated with disease progression
and poor prognosis. Biological background of this observa-
tion is linked to the modulation of angiogenic switch and
changes appearing in cytokine expression levels during tumor
transition from radial to invasive vertical and then metastatic
growth. The interest in VEGF is related to its priority role in
the process of neoangiogenesis, as well as with available tar-
get therapies blocking its activity. In compliance with litera-
ture data and results of presented study, the concentrations of
VEGF in sera of melanoma patients were significantly higher
than in control groups [10, 21–23].
Although clinical utility of VEGF in serum was the subject
of many publications, the results were ambiguous. Tas et al.
[23] noticed that VEGF concentration increased along with
the depth of the invasion. In our study, we have not detected
any dependencies between the concentrations of VEGF and
the depth of invasion. The lack of particular relationship be-
tween the concentrations of VEGF and the depth of invasion,
100.0<p100.0<p100.0<p100.0<p100.0<p100.0<p
800.0=p410.0=p960.0=p100.0<p100.0<p100.0<p
Fig 1 The MMP-9, TIMP-1,
VEGF, and YKL-40 serum level
distributions in the melanoma
patients at stages I, II, and III and
in the control group. The
horizontal lines indicate medians
in particular groups; all p values
concern the comparisons with the
control group
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as well as gender, age, location of primary site, lymph nodes
involvement, and clinical stages has been demonstrated by
Pelletier et al. [10] and Tas et al. [22].
The prognostic role of VEGF concentration in melanoma
was pointed by Ascierto et al. [11]. Authors showed that the
increased VEGF was related to the progression-free survival,
but not to patients’ overall survival. In our opinion, the prog-
nostic role of VEGF in serum is still unknown and further
studies are required.
The transitional research demonstrated that VEGF stimu-
lates endothelial cells to release MMPs. MMPs degrade extra-
cellular matrix and plasma membrane, as well as they enable
to release growth factors responsible for migration of endo-
thelial and cancer cells. The key role is assigned to MMP-2
and MMP-9. The tissue expression of those MMPs has an
effect on clinical data, for example, the increase of MMP-2
has been observed in patients at higher clinical stages, whereas
the expression of MMP-9 is combined with lower clinical
Fig. 2 Correlations between
MMP-9, TIMP-1, VEGF, and
YKL-40 serum levels in
melanoma patients
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stages [4, 8, 20]. Only few publications concerned the evalu-
ation of the concentrations ofMMP-2 andMMP-9 in serum of
patients with melanoma. In our study, the concentrations of
MMP-2 did not differentiate patients from control group.
However, the concentrations of MMP-9 were significantly
higher in those withmelanoma. Nevertheless, we did not dem-
onstrate an association between the concentration of MMP-9
and clinicopathological parameters, as well as DFS and OS.
Contrary to our study, Nikkola et al. [12] presented data
according to which MMP-9 had an effect on survival, al-
though these data included only patients with advanced/
metastatic melanoma.
Since the relation between the increase in the activity of
MMPs and the progression of melanoma seems to be quite
obvious, the role of tissue inhibitors of metalloproteinases
(TIMPs) is not easy to explain. The activity of TIMPs is re-
lated not only to the regulation of the reconstruction of extra-
cellular matrix but also to the regulation of cellular processes.
Table 2 Clinicopathological and
biochemical factors influencing
3-year disease-free survival and
3-year overall survival of
melanoma patients
Patient characteristics 3-year DFS (%) p value 3-year OS (%) p value
Gender
Female 76.3 0.040 86.6 0.103
Male 67.0 83.9
Age at the time of the diagnosis
≤55 years 75.7 0.310 87.1 0.664
>55 years 67.0 83.2
Anatomic site of primary tumor
Trunk 74.8 0.992 92.2 0.789
Upper extremity 72.7 79.7
Lower extremity 69.9 84.8
Other 64.8 64.8
Ulceration
Yes 84.1 0.003 94.9 0.002
No 60.8 76.4
Breslow scale














≤160 ng/ml (low) 81.4 0.014 88.8 0.050
>160 ng/ml (high) 61.0 81.5
YKL-40
≤80 ng/ml (low) 77.0 0.164 92.5 0.111
>80 ng/ml (high) 59.4 78.9
VEGF
≤399 pg/ml (low) 72.0 0.799 82.3 0.616
>399 pg/ml (high) 71.5 88.2
MMP-9
≤741 ng/ml (low) 68.8 0.583 80.8 0.258
>741 ng/ml (high) 71.5 89.7
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Observed dependencies between over-expression of TIMPs
and increase in tumor burden have confirmed the hypothesis
of TIMP role in tumor progression [24].
We have confirmed that the concentration of TIMP-1 was
significantly higher in melanoma patients than in control
group and that this increase has an effect on DFS and OS in
melanoma at locoregional stage. These data were compliant
with results of other researches, also devoted to patients with
metastatic disease [25]. However, in contrary to Yoshino et al.
[25], we have not observed any associations between the con-
centration of TIMP-1 and the depth of invasion, clinical stage,
or nodal status. Those findings are consistent with data pre-
sented by Tas et al. [14]. It is also worth mentioning that we
have not confirmed the relation between TIMP-1, age, and
ulceration, which was done by Tas et al. [14]. The utility of
prognostic role of TIMP-1 is a subject of research since, along
with other parameters, it may be a useful tool for monitoring
treatment and predicting the course of the disease [15, 26].
The effect of TIMPs on the disease progression is probably
related to their mechanisms of action regulated by the
activation of surface receptors. Therefore, TIMPs may act
directly on proliferation, migration, or angiogenesis, as well
as indirectly through regulation of MMP activity. Using those
mechanisms, TIMP-1 may mutually promote growth, as well
as may restrain the proliferation of tumor cells and regulate
apoptosis and angiogenesis [5].
Another biomarker involved in neoangiogenesis, inflam-
mation, and reconstruction of extracellular matrix is glycopro-
tein YKL-40. In our group of patients, the concentration of
YKL-40 was higher in those who recurred, as well as in those
in which the observation ended with death (the differences
were not statistically significant probably due to sample size).
In the paper presented by Schmidt et al. [16] which included
234 patients with stage I (n=162) and II (n=72), serum YKL-
40, along with thickness and ulceration, was an independent
prognostic factor of relapse-free survival and overall survival.
However, the concentrations of YKL-40 were not related to
the presence of ulceration, which is not consistent with results
obtained by us. Egberts et al. [27] showed that in melanoma










































Fig. 3 Three-year disease-free
survival and 3-year overall
survival in melanoma patients









































Fig. 4 Three-year disease-free
survival and 3-year overall
survival in melanoma patients
depending on YKL-40 level
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correlated significantly with the stage of disease. In stage IV
melanoma, only S100-B significantly (not YKL-40) correlates
with treatment response and survival. Because the data of
prognostic role of YKL-40 in melanoma are disputable, fur-
ther studies are needed [17].
The analysis of the interaction between serum bio-
markers revealed the most significant correlation coeffi-
cient between YKL-40, VEGF, and MMP-9. The partic-
ipation of YKL-40 in the processes of neoangiogenesis is
the effect of researches performed over the past few
years. Based on paper presented by Shao et al. [3],
YKL-40 may not only play a role in neoangiogenesis
acting as a potent angiogenic factor capable of stimulat-
ing tumor vascularization but also may induce FAK-
MAPK by signaling and up-regulating VEGF receptor 2
in endothelial cells. YKL-40 stimulates endothelial cells
to migration showing similar activity as VEGF [28].
The studies on the YKL-40 mechanisms of action, as
well as its utility in anti-YKL-40 therapies have been
the matter of recent studies [29]. Perhaps the results will
allow to explain not only the mode of action of YKL-
40 which remains enigmatic but also the discrepancy
between published papers. Riabov et al. [29] assumed
that the most important are overlapping mechanisms
such as biology of tumor cells, reaction of immune sys-
tem, as well as dependence between YKL-40 and TAM.
Salamon J et al. [30] on the other side presented very
interesting results with antibody against YKL-40. The
aim of their study was to evaluate the effect of anti-
YKL-40 monoclonal antibody on tumor growth and
morphology in xenograft model of human melanoma,
as well as pancreatic adenocarcinoma in scid mice. Au-
thors found that monotherapy with antibody targeting
YKL-40, rapidly enhances melanoma tumor size by in-
creasing the formation of new tumor vessels. They con-
cluded that YKL-40 could still be an interesting target
for anti-tumor therapy, but first, the mode of action of
YKL-40 should be solved.
Summary
The aim of presented study was to evaluate the clinical utility
of serum concentrations of VEGF, MMP-2, MMP-9, TIMP-1,
and YKL-40 in patients with melanoma at locoregional stage.
Marker selection was based on their role in cancerogenesis
and the possibility of the application of targeted therapy
[30–32]. We have proved that increased concentrations of
TIMP-1 were unfavorable prognostic factors for both
disease-free survival and overall survival, as well as for rela-
tion betweenYKL-40 and ulceration.We have also observed a
trend related to YKL-40 and recurrence. In order to verify
obtained results, further researches are required.
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